Calian Group Ltd., one of Canada's largest national health services organizations, supported a ground-breaking pilot study by Inagene Diagnostics in late 2020 to evaluate the “real-life” value of pharmacogenetic testing in optimizing the treatment of chronic pain and mental health conditions. Fifty Canadians who were being treated for chronic pain and concurrent mental health conditions were recruited from a busy clinic in PEI for the study in late 2020 to evaluate the impact pharmacogenetic testing could have on treatment, and on the time and cost burden involved in trialing different medications. The results were compelling and validated outcomes from previous studies.
